ocket No. ECV-5627

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re application of: Ralph Kafesjian

Application No.: 09/981,274

Filing Date: 10/17/01

For: SUPERCRITICAL FLUID EXTRACTION PROCESS FOR TISSUE PREPARATION

Assistant Commissioner of Patents Washington, D.C. 20231

Group Art Unit: 1744

Examiner: Unknown

TO TO ROOF DO

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to the duty of disclosure set forth under 37 CFR §§ 1.56, 1.97, and 1.98, Applicants enclose the references listed on the attached form PTO/SB/08. This submission is prior to receipt of a first Office Action on the merits and thus, pursuant to 37 CFR § 1.97, no fee is believed due. If a first Office Action on the merits is mailed prior to the mailing of this Information Disclosure Statement, please charge said fee or any other fee due to Deposit Account No. 501225 - ECV-5627.

Date: May 7, 2002

Respectfully submitted,

John Christopher James, Reg. No. 40,660

Edwards Lifesciences LLC

Law Department One Edwards Way

Irvine, California 92614

Telephone: (949) 250-6878 Facsimile: (949) 250-6850

CERTIFICATE OF MAILING

I hereby certify that the above-identified document is being deposited by (Express Mail No. EL 599143350US) with the United States Postal Service with sufficient postage in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on May 7, 2002.

Approved for use through 10/31/2002. OMB 0851-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to collection of information unless it contains a valid OMB cont

102		a valid Civib control number.		
Substitute for to the page 1	Comple	Complete if Known		
	Application Number	09/981,274		
INFORMATION DISCLOSURE	Filing Date	October 17, 2001		
STATEMENT BY APPLICANT	First Nam d Inventor	Ralph Kafesjian, et al.		
	Art Unit	1744		
(Use as many sheets as necessary)	Examiner Name	Unknown		
Sheet 1 of 3	Attorney Docket Number	ECV-5627		

			U.S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No	Document Number Number – Kind Code ² (If known)	.Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-2,900,644	08/25/59	Rosenberg, et al.	
	AB	US-3,927,422	12/23/75	Sawyer	
	AC	US-3,966,401	06/29/76	Hancock, et al.	
	AD	US-3,974,526	08/17/76	Dardik, et al.	
	AE	US-4,239,492	12/16/80	Holman, et al.	-
	AF	US-4,547,292	10/15/85	Zarchy	コ島田
	AG	US-4,553,974	11/19/85	Dewanjee	0 - 0
	AH	US-4,749,522	06/07/88	Kamarei	1011
	Al	US-4,755,593	07/05/88	Lauren	7 28 K
	AJ	US-4,770,780	09/13/88	Moses	0 0
	AK	US-4,816,159	03/28/89	Khosah, et al.	
	AL	US-4,824,570	04/25/89	Bethuel, et al.	
	AM	US-4,877,530	10/31/89	Moses	
	AN	US-4,880,543	11/14/89	Khosah, et al.	
	AO	US-5,084,239	01/28/92	Moulton, et al.	
	AP	US-5,723,012	03/03/98	Fages, et al.	
	-+	US-5,725,579	03/10/98	Fages, et al.	
	AR	US-5,877,005	03/02/99	Castor, et al.	
	AS	US-6,214,054 B1	04/10/01	Cunanan, et al.	

Evenia		FORE	IGN PATENT D	OCUMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to collection of information unless it contains a valid OMB control number.

MAY 0 7 2002

Complete if Known Substitute for form 1449A/PTO **Application Number** 09/981,274 **INFORMATION DISCLOSURE** Filing Date October 17, 2001 STATEMENT BY APPLICANT **First Named Inventor** Ralph Kafesjian, et al. **Art Unit** 1744 (Use as many sheets as necessary) **Examiner Name** Unknown Sheet of 3 **Attorney Docket Number** ECV-5627

	Office Code ³	Number⁴	Kind Code ⁵ (If known)		RECEIVED
AT	WO	85/04816 ~	A1	11/07/1985	707107
ΑU	WO	02/07785	A2	01/31/2002	TC 1700

	,	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	1 _	Fages, et al., "Supercritical Fluid Extraction: A New Way of Manufacturing Biomaterials," 21 st Annual Meeting of the Society for Biomaterials, March 18-22, 1995, San Francisco, California, p.236.	
	2 _	Fages, et al., "Use of supercritical CO2 for Bone Delipidation," Biomaterials 1994, Vol. 15, No. 9., pp 650-656.	1
	3 _	Fages, et al., "Use of Supercritical Fluid Extraction as a Method of Cleaning Anterior Cruciate Ligament Prostheses In Vitro and In Vivo Validation," ASAIO Journal 1998, pp. 278-288.	
	4_	McCoy, Michael "Industry Intrigued by CO2 as Solvent," C&EN Northeast News Bureau, pp.11-13, June 14, 1999 C&EN.	
	5 _	Mishra, et al. "Extraction and Purification of w-3 Fatty Acids With an Emphasis on Supercritical Fluid Extraction-A Review," Food Research International 26(3) (1993) 217-226.	\mid
	6	Chester, et al., "Supercritical Fluid Chromatography and Extraction," Analytical Chemistry, Vol. 68. No. 12, June 15, 1996, pp. 487-514.	\vdash
	7	Gueclue-Uestuendag, et al. "Correlating the Solubility Behavior of Fatty Acids, Mono-, Di-, and Triglycerides, and Fatty Acid Esters in Supercritical Carbon Dioxide," Ind. Eng. Chem. Res. 2000, 39(12), 4756-4766.	
	8_	Fages, et al., "Use of Supercritical CO2 for Bone Delipidation," Biomaterials 15(9):650-6, 1994 July – Abstract.	
		Fages, et al., "Use of Supercritical Fluid Extraction as a Method of Cleaning Anterior Cruciate Ligament Prostheses: in Vitro and in Vivo Validation," ASAIO Journal. 44(4):278-88, 1998 Jul-Aug. – Abstract.	
	10	Fages, et al., "Viral Inactivation of Human Bone Tissue Using Supercritical Fluid Extraction," ASAIO Journal. 44(4):289-93, 1998 Jul-Aug. – Abstract .	
	11_	Ishikawa, et al., "Sterilization of Microorganisms by the Supercritical Carbon Dioxide Micro-Bubble Method," Bioscience, Biotechnology & Biochemistry. 59(10):1949-50, 1995 Oct. – Abstract .	
	12 1	/an Bavel B., et al., "Supercritical Fluid Extraction of PCBs from Human Adipose Tissue for HRGC/LRMS analysis," Chemosphere.30(7):1229-36, 1995 Apr. – Abstract.	

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to collection of information unless it

Substitute	Substitute for form 144505			Complete if Known		
		Application Number	09/981,274			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	October 17, 2001	
			CANT	First Named Inventor	Ralph Kafesjian, et al.	
				Art Unit	1744	
~	(Use as man	y sheets as nece	ssary)	Examiner Name	Unknown	
Sheet	3	of	3	Attorney Docket Number	ECV-5627	

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	ner Cita No.								
	13	Frayssinet, P., et al., "Histological Integration of Allogeneic Cancellous Bone Tissue Treated by Supercritical CO2 Implanted in Sheep Bones," Biomaterials. 19(24):2247-53, 1998 Dec. – Abstract .							
	14	Koshevoi, et al., "Diffusion Coefficients of Triglycerides and Fatty Acids in Supercritical Carbon Dioxide," Pishch. Tekhnol. (2000), (2-3), 62-63 – Abstract .							
	15	Kim, et al., "Supercritical Fluid Extraction of Unsaturated Fatty Acids from Soybean Oil," Hwahak Konghak (1992), 30(6), 635-40 – Abstract .							

Examiner		15.	
Signature		Date	
		Considered	
*EXAMINER:	Initial if reference considered at the		

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

292_1

